Intellia Therapeutics, Inc. (NASDAQ:NTLA – Get Rating) – SVB Leerink issued their Q1 2023 earnings estimates for shares of Intellia Therapeutics in a research note issued on Monday, January 23rd. SVB Leerink analyst M. Foroohar expects that the company will post earnings of ($1.31) per share for the quarter. SVB Leerink currently has a "Outperform" rating and a $84.00 target price on the stock. The consensus estimate for Intellia Therapeutics' current full-year earnings is ($6.02) per share. SVB Leerink also issued estimates for Intellia Therapeutics' Q4 2023 earnings at ($1.26) EPS.

Get Intellia Therapeutics alerts:

Intellia Therapeutics (NASDAQ:NTLA – Get Rating) last posted its earnings results on Thursday, November 3rd. The company reported ($1.49) earnings per share for the quarter, missing the consensus estimate of ($1.31) by ($0.18). The firm had revenue of $13.27 million for the quarter, compared to analysts' expectations of $13.60 million. Intellia Therapeutics had a negative net margin of 859.92% and a negative return on equity of 47.79%.

A number of other research firms have also recently issued reports on NTLA. Morgan Stanley dropped their price target on shares of Intellia Therapeutics from $84.00 to $83.00 and set an "overweight" rating on the stock in a research note on Friday, November 4th. StockNews.com started coverage on shares of Intellia Therapeutics in a research note on Wednesday, October 12th. They issued a "sell" rating on the stock. Credit Suisse Group dropped their price target on shares of Intellia Therapeutics from $109.00 to $88.00 and set an "outperform" rating on the stock in a research note on Tuesday, December 6th. JMP Securities cut shares of Intellia Therapeutics from an "outperform" rating to a "market perform" rating in a research note on Thursday, January 19th. Finally, Chardan Capital lifted their price target on shares of Intellia Therapeutics from $121.00 to $129.00 and gave the company a "buy" rating in a research note on Monday, November 14th. One research analyst has rated the stock with a sell rating, three have assigned a hold rating and fifteen have given a buy rating to the company's stock. According to data from MarketBeat.com, the company presently has a consensus rating of "Moderate Buy" and a consensus target price of $102.00.

Intellia Therapeutics Price Performance

NASDAQ:NTLA opened at $38.53 on Tuesday. The firm has a market cap of $3.03 billion, a price-to-earnings ratio of -6.56 and a beta of 1.93. The company has a 50 day moving average price of $39.98 and a 200-day moving average price of $52.30. Intellia Therapeutics has a 1-year low of $32.44 and a 1-year high of $104.87.

Institutional Trading of Intellia Therapeutics

Several institutional investors and hedge funds have recently bought and sold shares of the stock. Eqis Capital Management Inc. raised its holdings in Intellia Therapeutics by 5.1% in the 3rd quarter. Eqis Capital Management Inc. now owns 4,345 shares of the company's stock valued at $243,000 after buying an additional 210 shares during the period. Xponance Inc. raised its holdings in Intellia Therapeutics by 5.2% in the 3rd quarter. Xponance Inc. now owns 4,250 shares of the company's stock valued at $238,000 after buying an additional 210 shares during the period. Steward Partners Investment Advisory LLC raised its holdings in Intellia Therapeutics by 10.2% in the 2nd quarter. Steward Partners Investment Advisory LLC now owns 2,368 shares of the company's stock valued at $123,000 after buying an additional 220 shares during the period. Amalgamated Bank raised its holdings in Intellia Therapeutics by 2.0% in the 3rd quarter. Amalgamated Bank now owns 11,352 shares of the company's stock valued at $635,000 after buying an additional 222 shares during the period. Finally, Zurcher Kantonalbank Zurich Cantonalbank raised its holdings in Intellia Therapeutics by 1.6% in the 3rd quarter. Zurcher Kantonalbank Zurich Cantonalbank now owns 15,777 shares of the company's stock valued at $883,000 after buying an additional 247 shares during the period. 85.61% of the stock is currently owned by hedge funds and other institutional investors.

Insider Transactions at Intellia Therapeutics

In other news, CEO John M. Leonard sold 6,673 shares of Intellia Therapeutics stock in a transaction on Wednesday, January 4th. The stock was sold at an average price of $37.21, for a total transaction of $248,302.33. Following the transaction, the chief executive officer now owns 766,825 shares in the company, valued at approximately $28,533,558.25. The transaction was disclosed in a legal filing with the SEC, which can be accessed through this hyperlink. In related news, EVP Laura Sepp-Lorenzino sold 2,508 shares of the business's stock in a transaction dated Wednesday, January 4th. The shares were sold at an average price of $37.21, for a total value of $93,322.68. Following the sale, the executive vice president now directly owns 19,959 shares in the company, valued at approximately $742,674.39. The sale was disclosed in a legal filing with the SEC, which can be accessed through this link. Also, CEO John M. Leonard sold 6,673 shares of the business's stock in a transaction dated Wednesday, January 4th. The shares were sold at an average price of $37.21, for a total transaction of $248,302.33. Following the completion of the sale, the chief executive officer now owns 766,825 shares in the company, valued at $28,533,558.25. The disclosure for this sale can be found here. Insiders have sold a total of 11,608 shares of company stock worth $431,934 in the last quarter. Company insiders own 2.60% of the company's stock.

Intellia Therapeutics Company Profile

(Get Rating)

Intellia Therapeutics, Inc, a genome editing company, focuses on the development of therapeutics. The company's in vivo programs include NTLA-2001, which is in Phase 1 clinical trial for the treatment of transthyretin amyloidosis; and NTLA-2002 for the treatment of hereditary angioedema, as well as other liver-focused programs comprising hemophilia A and hemophilia B, hyperoxaluria Type 1, and alpha-1 antitrypsin deficiency.

Featured Articles

• Get a free copy of the StockNews.com research report on Intellia Therapeutics (NTLA)
• High-Yield, Deep-Value Verizon Puts In A Bottom
• Should You Bet Against The Nasdaq 100 With This Inverse ETF?
• Can Coty Stock Emerge in 2023 With Upside
• Insiders Buy Archer Aviation, Is This Stock About To Take Off?
• Intuit Is About To Make a Move, But Which Way?

Receive News & Ratings for Intellia Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Intellia Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.